Crossmark

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau

Crossref DOI link: https://doi.org/10.1186/s40478-018-0562-9

Published Online: 2018-07-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Ameijde, Jeroen

Crespo, Rosa

Janson, Roosmarijn

Juraszek, Jarek

Siregar, Berdien

Verveen, Hanneke

Sprengers, Imke

Nahar, Tariq

Hoozemans, Jeroen J.

Steinbacher, Stefan

Willems, Roland

Delbroek, Lore

Borgers, Marianne

Dockx, Koen

Van Kolen, Kristof

Mercken, Marc

Pascual, Gabriel

Koudstaal, Wouter

Apetri, Adrian https://orcid.org/0000-0003-0424-1322
License Information

Text and Data Mining valid from 2018-07-12
More Information

Article History

Received: 31 May 2018

Accepted: 28 June 2018

First Online: 12 July 2018

Competing interest

: This work was fully funded by Janssen. Patent applications relating to CBTAU-22.1 and dmCBTAU-22.1 have been filed.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.